The European Renal Best Practice (ERBP) Advisory Board recently decided to follow up existing guidelines, and to publish position statements when new evidence would necessitate a change in the existing guideline [1].The purpose of this document is to provide guidance on the interpretation and relevancy of the current European Best Practice Guideline (EBPG) on dialysis strategy [2], in the light of the recently published Membrane Permeability Outcome (MPO) study [3].This position statement is intended to be considered in conjunction with the current guideline. It does not replace the guideline as we do not include a new systematic review of the literature. The MPO study specifically focused on the question whether the use of a high-, compared to a low-flux dialyser membrane, would have a measurable effect on survival.
Dialysis must control the body’s fluid content accurately in order to maintain optimal health. The only commonly used, practical and objective measurements we have to guide fluid removal are very inaccurate. Recent study has validated bioimpedance (BIA) as an objective measure of fluid and nutritional status in dialysis patients. There are a number of different methods suitable for routine use available to the clinician. Single-frequency whole-body BIA uses inexpensive equipment capable of almost instantaneous or continuous measurement. The results can be used to give an indication of a patient’s fluid content, nutrition and body composition when compared to appropriate reference values. Multiple-frequency whole-body BIA can be used to calculate excess fluid volume to within 1–2 liters. The equipment is more expensive than for single-frequency BIA, but the output is much easier to interpret. Multiple-frequency segmental BIA is more complicated to perform, but subject to less interference from changes in fluid distribution (e.g. resulting from hemodialysis or changes in posture). It is not suitable for routine use but could be considered as a gold standard for occasional clinical BIA.
29 December 2011 in Nephrology Dialysis Transplantation
Many anaemia management algorithms recommend changes to erythropoiesis-stimulating agent (ESA) doses based on frequent measurement of haemoglobin levels in keeping with the ESA datasheets. We designed a predictive anaemia algorithm based on ESA pharmacodynamics, which we hoped would improve compliance with haemoglobin targets and reduce workload. A new algorithm was designed which predicted the 3-month steady-state haemoglobin concentration following a change in ESA dose and only recommended a change if it was outside the range 10.5-12.5 g/dL. Data were collected prospectively for 3 months prior and 15 months subsequent to implementing the algorithm. A total of 214 prevalent dialysis patients were included in the audit. After 12 months, the haemoglobin concentration was 11.4 g/dL, near the midpoint of the target range, with a narrowing of the distribution (SD 1.46 to 1.25 g/dL, P < 0.0001). The proportion of patients with a haemoglobin level in the target range increased from 56% to 66% (P < 0.001) principally due to a reduction in the number of patients with high haemoglobin levels. There was no significant change in the ESA dose over the audit period. The number of prescription changes fell from 1/2.5 months to 1/6.1 months after 12 months (P < 0.001). Switching prevalent haemodialysis patients to a predictive anaemia management algorithm improved compliance with haemoglobin targets, reduced the number of patients with high haemoglobin levels and reduced the number of ESA dose changes required.